Prometheus Biosciences (RXDX)

Cash on Hand as of March 2023 : A$1.14 Billion

According to Prometheus Biosciences's latest financial reports the company has A$1.14 Billion in cash and cash equivalents.
A company’s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.

Prometheus Biosciences - Cash on Hand chart (from 2020 to 2023)

Cash on Hand by year

Year	Cash on Hand	Change
2022-12-31	A$1.02 B	188.13%
2021-12-31	A$0.35 B	403.4%
2020-12-31	A$70.48 M	1009.04%
2019-12-31	A$6.35 M

Cash on Hand for similar companies or competitors

Company	Cash on Hand	differencediff.	Country
Epizyme EPZM	N/A	N/A	🇺🇸 USA
Agenus AGEN	A$72.04 M	-93.72%	🇺🇸 USA
Akebia Therapeutics AKBA	A$54.72 M	-95.23%	🇺🇸 USA

What is the market capitalization of a company?

The market capitalization sometimes referred as Marketcap, is the value of a publicly listed company.
In most cases it can be easily calculated by multiplying the share price with the amount of outstanding shares.

DISCLAIMER

CompaniesMarketCap is not associated in any way with CoinMarketCap.com
Stock prices are delayed, the delay can range from a few minutes to several hours.
Company logos are from the CompaniesLogo.com logo database and belong to their respective copyright holders. Companies Marketcap displays them for editorial purposes only.

Contact

For inquiries or if you want to report a problem write to hello@8marketcap.com

Links

- Privacy policy

- Terms and conditions

Prometheus Biosciences (RXDX) - Cash on Hand

Cash on Hand as of March 2023 : A$1.14 Billion